Dive into the archives.
- Dirucotide Does Not Meet Primary Endpoint in Phase III Trial In Secondary Progressive MS
July 27, 2009 – Eli Lilly and Company and BioMS Medical Corp. today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no [...]
- 11th Case of PML Reported With Tysabri
The 11the patient on Tysabri has developed a potentially deadly brain infection.
This is what happened when three people who were on Tysabri and other medications for Multiple Sclerosis had previously contracted the brain infection and two died, according to InjuryBoard.com which tracks such drug reactions. Then, the drug was taken off the market briefly.
Biogen Idec, [...]
- Ribavirin as Potential Treatment for MS?
Thursday July 23, 2009, 11:16 am EDT
BELGRADE, SERBIA, July 23 /PRNewswire-FirstCall/ – Hard to Treat Diseases, Inc. (HTDS:PK) http://www.htdsmedical.com reports that researchers in its Slavica BioChem division have advised of some significant findings regarding its research into the use of Ribavirin in the treatment of Multiple sclerosis (MS).
The research team has been conducting experiments using [...]
- Merck Sumbits Cladribine Application for EU Approval
July 23, 2009 — 9:05am ET | By John Carroll
Racing to beat Novartis to the world’s biggest drug markets with a new oral therapy for multiple sclerosis, Merck KGaA has filed for regulatory approval of cladribine in Europe and plans to file in the U.S. later this quarter.
The application brings Merck ”closer to the possibility of providing an [...]
- Predicting Relapses Means Preventing Them
The ability to predict the spatial frequency of relapses in multiple sclerosis (MS) would enable physicians to decide when to intervene more aggressively and to plan clinical trials more accurately.
Methods: In the current study our objective was to determine if subsets of genes can predict the time to the next acute relapse in patients with [...]
- NIH Deepens Investment In Avonex and Copaxone Combination Study
Article Date: 22 Jul 2009 – 4:00 PDT
The first large-scale “CombiRX” clinical trial testing the combined use of FDA-approved interferon beta-1a (Avonex®) and glatiramer acetate (Copaxone®) to treat relapsing-remitting MS has just received a $19-million renewal grant from the National Institutes of Health. This is the largest MS trial ever supported by the [...]
- Exercise Your Brain: Online Game Launched for PWMS
Article Date: 16 Jul 2009 – 3:00 PDT
The MS Technology Collaborative has created a new way for people living with multiple sclerosis (MS) to exercise their brain power. The Collaborative, an alliance of Bayer HealthCare Pharmaceuticals, Microsoft, and the National Multiple Sclerosis Society, today announced the launch of MyBrainGames, a free suite of online games [...]
- Smoking Probably Accelerates MS
ScienceDaily (July 14, 2009) — Patients with multiple sclerosis who smoke appear to experience a more rapid progression of their disease, according to a new report.
Cigarette smokers are at higher risk of developing multiple sclerosis (MS), according to background information in the article. However, the effect of smoking on the progression of MS remains uncertain.
Brian [...]
- As Lilly, Pfizer Lobby Against Obama Healthcare Plan, Their Execs Enjoy Gold-Plated Coverage
By Jim Edwards July 10th, 2009
Eli Lilly, Pfizer, and PhRMA all oppose a pubic heathcare plan, according to the Center for Responsive Politics. Instead, they’d like to see individual insurance mandates and an expansion of health savings accounts. But their top executives have health insurance plans which include cash payments of thousands of dollars and [...]
- Tired of Patients vs. Profits? Quit Throwing Fuel on the Fire
By Trista Morrison | July 9th, 2009
Is anyone else tired of hearing that drug companies care more about profits than patients? Me, too. But even more tiresome than the anti-pharma rhetoric is the fact that industry keeps pouring fuel on the fire.
True, most drug makers got into the business in order to help [...]
